Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
13.36 USD | -4.16% | -4.94% | -37.79% |
04-25 | Truist Securities Cuts Sage Therapeutics' Price Target to $18 From $22, Hold Rating Maintained | MT |
04-25 | Transcript : Sage Therapeutics, Inc., Q1 2024 Earnings Call, Apr 25, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.79% | 839M | |
+8.66% | 105B | |
-0.85% | 104B | |
+5.79% | 22.94B | |
-12.55% | 22.34B | |
-7.01% | 19.25B | |
-37.08% | 17.08B | |
-9.26% | 16.96B | |
+8.08% | 14.16B | |
+39.55% | 12.63B |
- Stock Market
- Equities
- SAGE Stock
- News Sage Therapeutics, Inc.
- Sage Therapeutics' Treatment for Parkinson's-related Cognitive Deficit Improves Patient Function, Study Data Shows